Coupling to a cancer-selective heparan-sulfate-targeted branched peptide can by-pass breast cancer cell resistance to methotrexate

• Published in: Oncotarget Vol. 8; no. 44; pp. 76141 - 76152
• Main Authors: Depau, Lorenzo, Brunetti, Jlenia, Falciani, Chiara, Scali, Silvia, Riolo, Giulia, Mandarini, Elisabetta, Pini, Alessandro, Bracci, Luisa
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 29.09.2017
• Subjects: Research Paper; drug-resistance; methotrexate; peptides; heparan sulfate
• ISSN: 1949-2553; 1949-2553
• DOI: 10.18632/oncotarget.19056

Cancer-selective tetra-branched peptides, named NT4, can be coupled to different functional units for cancer cell imaging or therapy. NT4 peptides specifically bind to lipoprotein receptor-related proteins (LRP) receptors and to heparan sulfate chains on membrane proteoglycans and can be efficiently internalized by cancer cells expressing these membrane targets. Since binding and internalization of NT4 peptides is mediated by specific NT4 receptors on cancer cell membranes and this may allow drug resistance produced by drug membrane transporters to be by-passed, we tested the ability of drug-armed NT4 to by-pass drug resistance in cancer cell lines. We found that MTX-conjugated NT4 allows drug resistance to be by-passed in MTX-resistant human breast cancer cells lacking expression of folate reduced carrier. NT4 peptides appear to be extremely promising cancer-selective targeting agents that can be exploited as theranostics in personalized oncological applications.